Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 7:9:750185.
doi: 10.3389/fcell.2021.750185. eCollection 2021.

Promising Applications of Nanoparticles in the Treatment of Hearing Loss

Zilin Huang  1   2 , Qiang Xie  1   2 , Shuang Li  1   2 , Yuhao Zhou  1   2 , Zuhong He  1   2 , Kun Lin  1   2 , Minlan Yang  1   2 , Peng Song  1   2 , Xiong Chen  1   2
Affiliations
Review

Promising Applications of Nanoparticles in the Treatment of Hearing Loss

Zilin Huang et al. Front Cell Dev Biol. .

Abstract

Hearing loss is one of the most common disabilities affecting both children and adults worldwide. However, traditional treatment of hearing loss has some limitations, particularly in terms of drug delivery system as well as diagnosis of ear imaging. The blood-labyrinth barrier (BLB), the barrier between the vasculature and fluids of the inner ear, restricts entry of most blood-borne compounds into inner ear tissues. Nanoparticles (NPs) have been demonstrated to have high biocompatibility, good degradation, and simple synthesis in the process of diagnosis and treatment, which are promising for medical applications in hearing loss. Although previous studies have shown that NPs have promising applications in the field of inner ear diseases, there is still a gap between biological research and clinical application. In this paper, we aim to summarize developments and challenges of NPs in diagnostics and treatment of hearing loss in recent years. This review may be useful to raise otology researchers' awareness of effect of NPs on hearing diagnosis and treatment.

Keywords: cochlear implant; drug delivery system; hair cells; hearing loss; imaging; nanomaterials.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Applications of nanomaterials in hearing loss. (A) Nanoparticles (NPs) can serve in drug delivery systems to the inner ear with intratympanic (IT) injection. (B) Nanomaterials can be used as contrast agents in otologic imaging. (C) Application of nanomaterial in cochlear implants (CIs). Part of the material in Figure is from https://smart.servier.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Buniel M. C., Geelan-Hansen K., Weber P. C., Tuohy V. K. (2009). Immunosuppressive therapy for autoimmune inner ear disease. Immunotherapy 1 425–434. 10.2217/imt.09.12 - DOI - PMC - PubMed
    1. Burblies N., Schulze J., Schwarz H. C., Kranz K., Motz D., Vogt C., et al. (2016). Coatings of different carbon nanotubes on platinum electrodes for neuronal devices: preparation, cytocompatibility and interaction with spiral ganglion cells. PLoS One 11:e0158571. 10.1371/journal.pone.0158571 - DOI - PMC - PubMed
    1. Cai Y., Edin F., Jin Z., Alexsson A., Gudjonsson O., Liu W., et al. (2016). Strategy towards independent electrical stimulation from cochlear implants: guided auditory neuron growth on topographically modified nanocrystalline diamond. Acta Biomater. 31 211–220. 10.1016/j.actbio.2015.11.021 - DOI - PubMed
    1. Chadha S., Cieza A. (2017). Promoting global action on hearing loss: world hearing day. Internat. J. Audiol. 56 145–147. 10.1080/14992027.2017.1291264 - DOI - PubMed
    1. Chandrasekhar S. S., Rubinstein R. Y., Kwartler J. A., Gatz M., Connelly P. E., Huang E., et al. (2000). Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol. Head Neck Surg. 122 521–528. 10.1067/mhn.2000.102578 - DOI - PubMed